- Conference Call/Webcast at 4:30 p.m. Eastern Time Today -
IRVINE, Calif., March 13 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular patient temperature management therapies, today reported on its corporate progress and financial results for the fourth quarter and year ended December 31, 2007.
Revenue for the fourth quarter of 2007 was a record $2.7 million, compared to $2.0 million in the fourth quarter of 2006. Revenue for the full year 2007 was also a record of $9.1 million, compared to $6.0 million in 2006. These results were due to growth in sales of intravascular temperature management systems, as well as increased sales of catheters due to the growing installed base.
"We are proud to report our strongest quarter and year in Alsius history, which is a direct result of our continued investment in developing the leading intravascular temperature management solutions," said Bill Worthen, President and CEO of Alsius. "Our customers are becoming increasingly aware of the importance of precise temperature management in critically ill patients and recognize the value of our technology as the right solution. Our efforts in 2008 will be focused on continuing to develop the market for our products -- increasing awareness of the importance of temperature management and the benefits of our technology versus conventional approaches."
Additional Fourth Quarter and Full Year 2007 Financial Results
In the fourth quarter of 2007, gross profit was $0.8 million, compared to $0.3 million in the fourth quarter of 2006. For the full year 2007, gross profit was $1.8 million, compared to a loss of $0.2 million for the same period the prior year.
Total operating expenses in the fourth quarter of 2007 were $6.4 million compared to $3.8 million in the same period of 2006. Included in the cost of revenue and operating expenses for the fourth quarter of 2007 were non-cash, stock compensation expenses of $1.3 million compared to $0.1 million for the fourth quarter of 2006. Total operating expenses for the full year 2007 were $20.6 million, compared to $13.3 million in 2006. Included in the full year 2007 expenses were non-cash, stock compensation expenses of $3.4 million, compared to $0.6 million in 2006. The increase in total operating expenses for the fourth quarter and full year 2007 was primarily attributable to the growth in Alsius' direct sales force and marketing activities to support worldwide market expansion.
Net loss for the fourth quarter of 2007 was $5.7 million, or $0.31 per share, compared to $4.8 million, or $0.44 per share, for the fourth quarter of 2006. The 2007 year-end net loss was $22.2 million, or a loss per share of $1.49, compared to $17.6 million, or a loss per share of $1.60, in the same period a year ago.
Cash and cash equivalents were $24.4 million at December 31, 2007, compared to $29.5 million at September 30, 2007, and $0.6 million at December 31, 2006. Cash used for operating activities during the fourth quarter of 2007 was $3.7 million. In addition, the company repaid $0.8 million of debt, in the fourth quarter of 2007. Alsius' independent registered public accounting firm's report on the company's financial statements for the fiscal year ended December 31, 2007 will include a going concern qualification. The company anticipates raising capital prior to the second quarter of 2009 to support growth, consistent with its business plan.
Highlights and Accomplishments
"We believe our accomplishments in 2007 have helped us build a strong foundation for future success," added Mr. Worthen. "By the end of last year, approximately 560 Alsius systems had been installed at major acute care hospitals in the U.S. and abroad, with over 15,000 patients treated to date. Not only is the list of hospitals that have expressed interest in our products growing, but many existing customers are recognizing the potential to use our technology in different areas of the hospital. As a result, more hospitals are ordering multiple systems."
Alsius achieved a number of key milestones last year and during the
first quarter of this year, including the following:
-- Corporate Achievements
- Closed the merger with Ithaka Acquisition Corp., in June 2007, which
provided Alsius with capital to support increased sales and
marketing and product development efforts.
- Successfully completed an early warrant exercise program in January
2008, which simplified the company's capital structure by reducing
the number of outstanding warrants.
-- Sales and Marketing Momentum
- Enhanced its sales and marketing infrastructure, including hiring a
new director of U.S. sales, a corporate accounts manager, a sales
manager for the Asia/Pacific region, a national service manager and
a marketing manager to oversee the warming market.
- Catheter utilization rates, or the number of catheters used per
machine per month, exceeded expectations for 2007.
- Average sale price of Alsius systems remained on target and stable.
- Received important endorsements from major hospital group purchasing
organizations representing nearly 3,000 acute care hospitals,
including an exclusive three-year sales, marketing and customer
service contract from Amerinet, and a three-year contract from
Mid-Atlantic Group Network of Shared Services (MAGNET).
- Initiated process to obtain regulatory approval in additional
international markets, including Japan.
-- Product Expansion
- Launched two major new products: the Thermogard XP (TM) Temperature
Management system, which is designed to provide an enhanced level of
therapeutic cooling power; and the Quattro (TM) catheter, a
four-balloon heat exchange catheter that provides increased surface
area and power with triple lumen central venous access.
-- Clinical Validation
- Alsius' products were featured in over 85 articles, abstracts and
presentations in peer-reviewed journals or medical meetings around
the world, including the Congress of Neurological Surgeons, the
American College of Surgeons, European Burns Association, the
International Hypothermia Symposium, and the Neurocritical Care
Society.
- The peer-reviewed journal, Critical Care, published a study in
August comparing different cooling methods and concluded that Alsius
intravascular cooling demonstrated the fastest cooling rates and was
the most reliable for maintaining stable body temperature. The study
evaluated Alsius intravascular temperature management, conventional
(cold intravenous fluids and/or cold packs), water and air
circulating blankets and water circulating gel-coated pads.
Conference Call Details
Alsius will host a conference call and webcast on March 13, 2008 at 4:30 p.m. Eastern Time. To participate in the teleconference, participants in the U.S. and Canada may call 877-440-5791 while international callers should dial 719-325-4879. No password is required for the live teleconference. To access the webcast, please go to the Investor Relations page on our website http://www.alsius.com.
A telephone replay of the conference call will be available 90 minutes after the call concludes on March 13 through March 31, 2008. For replays, dial 888-203-1112 (U.S. and Canada) and 719-457-0820 (international). The replay password is 3423016. An archived copy of the webcast will also be available for a period of time in the Investor Relations tab of http://www.alsius.com.
About Alsius
Alsius, headquartered in Irvine, CA, is a commercial-stage medical device company that develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit http://www.alsius.com.
Safe Harbor
This press release may contain statements regarding plans and
expectations for the future that constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical fact are
forward-looking. Such forward looking statements, based upon the current
beliefs and expectations of Alsius' management, are subject to risks and
uncertainties, which could cause actual results to differ significantly
from those described in the forward-looking statements. The information in
this release should be read in light of such risks. Additional information
concerning these risks and uncertainties are contained in Alsius' filings
with the Securities and Exchange Commission, which can be accessed
electronically on the Securities and Exchange Commission website at
http://www.sec.gov or through the Investor Relations page on
http://www.alsius.com.
--Tables to follow--
ALSIUS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In Thousands, Except Share and Per Share Data)
Three Months Year
Ended December 31, Ended December 31,
2007 2006 2007 2006
Revenue $2,709 $1,958 $9,114 $5,979
Cost of revenue* 1,955 1,634 7,341 6,167
Gross margin 754 324 1,773 (188)
Operating expenses:
Research and development* 1,325 868 3,920 2,948
Sales and marketing* 3,456 2,018 11,211 6,045
General and administrative* 1,646 909 5,471 4,352
Total operating expenses 6,427 3,795 20,602 13,345
Loss from operations (5,673) (3,471) (18,829) (13,533)
Other income (expense):
Interest income 270 4 708 76
Interest expense (262) (966) (4,149) (2,064)
Other income (expense) - (394) 35 (2,057)
Net loss $(5,665) $(4,827) $(22,235) $(17,578)
Net loss per share - basic
and diluted $(0.31) $(0.44) $(1.49) $(1.60)
Weighted average shares
outstanding - basic and
diluted 18,253,500 10,974,100 14,873,916 10,974,100
* Stock-based compensation is
included in the above amounts
as follows:
Cost of revenue $98 $6 $238 $23
Research and development 226 12 582 48
Sales and marketing 357 46 985 149
General and administrative 581 71 1,582 354
Total stock-based
compensation expenses $1,262 $135 $3,387 $574
ALSIUS CORPORATION
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share data)
December 31, December 31,
2007 2006
ASSETS
Current assets:
Cash and cash equivalents $24,427 $647
Accounts receivable, net of allowances of
$44 and $13 2,162 1,517
Inventories 6,680 2,368
Prepaid expenses 284 189
Total current assets 33,553 4,721
Property and equipment, net 1,034 360
Evaluation equipment, net 673 636
Other assets 342 523
TOTAL $35,602 $6,240
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $2,732 $2,361
Accrued liabilities 1,916 1,785
Current portion of long-term debt 3,200 9,318
Current portion of capital lease obligations 25 20
Total current liabilities 7,873 13,484
Long-term debt-less current portion 3,569 1,343
Warrant liabilities and embedded derivatives - 5,030
Capital lease obligations, less current portion 82 95
Other liabilities 66 -
Commitments and contingencies
Redeemable convertible preferred stock - 46,643
Shareholders' equity (deficit):
Preferred stock, $0.0001 par value, 1,000,000
shares authorized; no shares issued or
outstanding - -
Common stock, $0.0001 par value, 75,000,000
shares authorized: 18,253,500 shares issued
and outstanding at December 31, 2007 2 -
Common stock, no par value, 20,000,000 shares
authorized: 78,942 shares issued and outstanding
at December 31, 2006 - 16,430
Additional paid-in capital 122,237 -
Deferred stock-based compensation - (793)
Accumulated deficit (98,227) (75,992)
Total shareholders' equity (deficit) 24,012 (60,355)
TOTAL $35,602 $6,240
'/>"/>
| SOURCE Alsius Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
2. Alsius Corporation Announces Program for Early Exercise of Warrants
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Brooke Franchise Corporation Announces Selected July Results
5. MedThink Communications Retained by NanoBio Corporation
6. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |